[Local obliterative hepatic endophlebitis and hepatosclerosis as a consequence of the therapy of infantile leukosis].
D000970:Antineoplastic Agents / Q000009:adverse effects*; D001344:Autopsy; D056486:Chemical and Drug Induced Liver Injury; D003520:Cyclophosphamide / Q000009:adverse effects; D005260:Female; D006503:Hepatic Veins; D006801:Humans; D007223:Infant; D007938:Leukemia / Q000188:drug therapy*; D008107:Liver Diseases / Q000473:pathology; D008198:Lymph Nodes / Q000473:pathology; D015122:Mercaptopurine / Q000009:adverse effects; D008727:Methotrexate / Q000009:adverse effects; D010689:Phlebitis / Q000139:chemically induced* / Q000473:pathology; D012598:Sclerosis; D013154:Spleen / Q000473:pathology
D000970:Antineoplastic Agents; D003520:Cyclophosphamide; D015122:Mercaptopurine; D008727:Methotrexate
Therapiebedingte lokale Endophlebitis hepatica obliterans und Hepatosklerose bei kindlicher Leukose.